Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | LARS1 | Q9P2J5 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5019552 | 0.94 | TP53 (0.35) | LARS1 | |
| SCHEMBL16706966 | 0.94 | TP53 (0.35) | LARS1 | |
| SCHEMBL16706967 | 0.94 | TP53 (0.35) | LARS1 | |
| SCHEMBL5019545 | 0.93 | LMNA (0.36) | HTR2BLARS1 | |
| SCHEMBL460571 | 0.91 | LARS1 (0.44) | HTR2CHTR2BLARS1 | |
| SCHEMBL13073614 | 0.90 | TP53 (0.33) | LARS1 | |
| SCHEMBL13074078 | 0.90 | TP53 (0.33) | LARS1 | |
| SCHEMBL13073748 | 0.90 | TP53 (0.33) | LARS1 | |
| SCHEMBL15075004 | 0.89 | ALDH1A1 (0.37) | — | |
| SCHEMBL3446400 | 0.89 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8530452-B2 | Tricyclic boron compounds for antimicrobial therapy | MICURX PHARMACEUTICALS, INC. (KY) | 2013-09-10 | — | — | US | disclosed |
| US-20130165411-A1 | TRICYCLIC BORON COMPOUNDS FOR ANTIMICROBIAL THERAPY | MICURX PHARMACEUTICALS, INC. (KY) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165411-A1 | TRICYCLIC BORON COMPOUNDS FOR ANTIMICROBIAL THERAPY | TBCA, TBCB, BTD | HTR2C 4401/4885HTR2B 3925/4885LARS1 858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.